Search

Displaying results 1931 - 1940 of 4234 in total
  1. Drug

    Diosmin

    go.drugbank.com/drugs/DB08995
    ApprovedInvestigational

    Chronic venous insufficiency is a common condition the western population. Compression and pharmacotherapy are frequently used to manage chronic venous insufficiency, improving circulation and symptoms of venous disease. Diosmin is a bio...

  2. Drug

    Trastuzumab emtansine

    go.drugbank.com/drugs/DB05773
    ApprovedInvestigational

    Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity.

  3. Drug

    Aluminum zirconium pentachlorohydrate

    go.drugbank.com/drugs/DB11147
    Approved

    Aluminum zirconium pentachlorohydrate is a common active ingredient in personal care products as an antiperspirant agent.

  4. Drug

    Hexafluronium

    go.drugbank.com/drugs/DB00941
    Approved

    Hexafluronium bromide is a neuromuscular blocking agent used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of suxamethonium during surgery. It is known to bind and block the activity of plasma cholineste...

  5. Drug

    Clobutinol

    go.drugbank.com/drugs/DB09004
    ApprovedWithdrawn

    Clobutinol is a cough suppressant that is withdrawn from the US and EU markets. Clobutinol may prolong the QT interval. In 2007, Clobutinol was determined to cause cardiac arrhythmia in some patients.

  6. Drug

    19-norandrostenedione

    go.drugbank.com/drugs/DB01434
    ExperimentalIllicit

    After 2005, 19-Norandrostenedione was regulated in the United States as a schedule III controlled substance, as well as banned from use in competitive sports by the World Anti-Doping Agency. … In the body 19-norandrostenedione is rapidly metabolized into [nandrolone], also known as nortestosterone.

  7. Drug

    Apadamtase alfa

    go.drugbank.com/drugs/DB15164
    ApprovedInvestigational

    [A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP.

  8. Drug

    Mobocertinib

    go.drugbank.com/drugs/DB16390
    ApprovedInvestigationalWithdrawn

    It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the _EGFR_ gene,[L38368] which are typically associated with a poorer prognosis (as

  9. Drug

    MPI-674

    go.drugbank.com/drugs/DB05749
    Experimental

    It is developed for the treatment of several serious women’s health conditions including endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding (AUB). … AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen.

  10. Drug

    Cyanocobalamin Co-60

    go.drugbank.com/drugs/DB09387
    ApprovedWithdrawn

    Cyanocobalamin Co-60 was used for the diagnosis of pernicious anemia, but now it is withdrawn from the market in the US for unknown reasons.